Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Early virological failure with a combination of tenofovir, didanosine and efavirenz.

Antiviral therapy - 1 Jan 2005

Podzamczer Daniel, Ferrer Elena, Gatell Josep Maria, Niubo Jordi, Dalmau David, Leon Agathe, Knobel Hernando, Polo Carolina, Iniguez Daniel, Ruiz Isaac

Abstract excerpt

OBJECTIVE: To describe the occurrence of a high early virological failure (VF) rate and development of resistance mutations in antiretroviral-naive patients receiving tenofovir, didanosine and efavirenz. METHODS: HIV-infected antiretroviral-naive patients with viral load > or =30 000 copies/ml were enrolled in a pilot randomized trial of tenofovir/didanosine (250 mg)/ efavirenz with (arm A) or without (arm B)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkynes
Share to Benzoxazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Didanosine

Share to Lopinavir

Share to Organophosphonates

Share to Oxazines

Share to Pyrimidinones

Share to Tenofovir

Source

Identifiers

PMID: 15751775

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Early virological failure with a combination of tenofovir, didanosine and efavirenz.PMID 15751775Read ↗

Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy.Semantic proximity Read ↗

High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir.Semantic proximity Read ↗

Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.Semantic proximity Read ↗

Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.Semantic proximity Read ↗

Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.Semantic proximity Read ↗

Analysis of early resistance development at the first failure timepoint in elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate-treated patients.Semantic proximity Read ↗

Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study.Semantic proximity Read ↗

Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.Semantic proximity Read ↗

Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations.Semantic proximity Read ↗

Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz.Semantic proximity Read ↗

Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine.Semantic proximity Read ↗

Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.